Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cellect Biotechnology Ltd ADR (APOP)

Cellect Biotechnology Ltd ADR (APOP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and...

APOP : 13.17 (+0.38%)
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held...

APOP : 13.17 (+0.38%)
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.

Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter

APOP : 13.17 (+0.38%)
The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals

Special General Meeting of Shareholders Scheduled for September 19, 2021

APOP : 13.17 (+0.38%)
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals

Transaction Expected to Close in the 2021 Third Quarter

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial

Results Support Ongoing Clinical Development of ApoGraft in U.S.

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported...

APOP : 13.17 (+0.38%)
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger

Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021

Promising Progress on Clinical D evelopment Progress , Collaboration s and Partnering

APOP : 13.17 (+0.38%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar